LDL-C THERAPEUTIC TARGET ATTAINMENT IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE

被引：0
|
作者：
Underberg, James [1 ]
Harada-Shiba, Mariko [2 ]
Hegele, Robert A. [3 ]
McCullough, Peter A. [4 ]
DiGioia, Kenneth [5 ]
Jurecka, Agnieszka [5 ]
Stefanutti, Claudia [6 ]
Blom, Dirk [7 ]
机构：
[1] NYU, Ctr Prevent Cardiovasc Dis, New York, NY USA
[2] Natl Cerebral & Cardiovasc Ctr, Res Inst, Osaka, Japan
[3] Robarts Res Inst, London, ON, Canada
[4] Baylor Univ, Med Ctr, Dallas, TX USA
[5] Aeger Pharmaceut, Cambridge, MA USA
[6] Sapienza Univ Rome, Rome, Italy
[7] Univ Cape Town, Cape Town, South Africa
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷
关键词：
D O I：
10.1016/j.atherosclerosissup.2018.04.468
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
P5.046
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [1] Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide
    Giammanco, Antonina
    Cefalu, Angelo B.
    Noto, Davide
    Averna, Maurizio R.
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (23) : 3773 - 3783
  • [2] Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia
    Kim, Sang-Hyun
    Baek, Sang Hong
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (02) : 155 - 156
  • [3] Lomitapide for the Management of Homozygous Familial Hypercholesterolemia
    deGoma, Emil M.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (02) : 109 - 118
  • [4] AGE AND LDL-C RANGES IN A DEFINED HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENT POPULATION
    Raal, F.
    Isaac, B.
    ATHEROSCLEROSIS, 2014, 235 (02) : E57 - E57
  • [5] LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
    Blom, Dirk J.
    Fayad, Zahi A.
    Kastelein, John J. P.
    Larrey, Dominique
    Makris, Lukas
    Schwamlein, Charles
    Bloeden, LeAnne
    Underberg, James
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (02) : 273 - 282
  • [6] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Awad Alshahrani
    Naji Kholaif
    Mutaz Al-Khnifsawi
    Hawazen Zarif
    Moeber Mahzari
    Advances in Therapy, 2024, 41 : 837 - 846
  • [7] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Alshahrani, Awad
    Kholaif, Naji
    Al-Khnifsawi, Mutaz
    Zarif, Hawazen
    Mahzari, Moeber
    ADVANCES IN THERAPY, 2024, 41 (02) : 837 - 846
  • [8] Torcetrapibiatorvastatin substantially raises HDL-C and markedly lowers LDL-C in patients with homozygous familial hypercholesterolemia
    Raal, F. J.
    Marais, A. D.
    Gagne, C.
    Gaudet, D.
    Viljoen, J.
    Hemphill, L.
    Durham, K.
    Thuren, T.
    Shears, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 204 - 204
  • [9] REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
    Ager, M.
    Phillips, H.
    VALUE IN HEALTH, 2018, 21 : S93 - S93
  • [10] RESOLUTION OF PLANAR XANTHOMA IN A PATIENT WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE
    Underberg, James
    Schwartzbard, Arthur
    CLINICAL CARDIOLOGY, 2015, 38 : 11 - 11
12345